Bacteria News and Research

RSS

WSU researcher receives NSF fund to study on antibiotic resistance

In March, the director-general of the World Health Organization warned of "an end to modern medicine as we know it."

3 Nov 2012

Mass spectrometry can help visualize how drugs work inside living cells to kill infectious microbes

Weill Cornell Medical College researchers report that mass spectrometry, a tool currently used to detect and measure proteins and lipids, can also now allow biologists to "see" for the first time exactly how drugs work inside living cells to kill infectious microbes.

3 Nov 2012

Researcher identifies 71 genetic regions newly associated with inflammatory bowel disease

In one of the largest studies of its kind ever conducted, an international team of scientists has thrown new light on the genetic basis of the inflammatory bowel diseases (IBD).

3 Nov 2012

MH6 vaccine shows promise in treating meth addiction

Scientists at The Scripps Research Institute (TSRI) have performed successful tests of an experimental methamphetamine vaccine on rats. Vaccinated animals that received the drug were largely protected from typical signs of meth intoxication.

2 Nov 2012

Nisin may slow or prevent squamous cell head and neck cancers

Nisin, a common food preservative, may slow or stop squamous cell head and neck cancers, a University of Michigan study found.

1 Nov 2012

Microbiologists confirm existence of new tick disease in Switzerland

Until now, we knew that ticks primarily transmit two pathogens to humans in Switzerland: the bacterium Borrelia burgdorferi - which causes borreliosis - and the early-summer-meningoencephalitis virus, which can cause cerebral inflammation. Now, microbiologists from the University of Zurich confirm the existence of another tick disease in Switzerland - neoehrlichiosis.

1 Nov 2012

Scientists solve mystery behind what triggers the herpes virus to become active again

The mere mention of the word "herpes" usually conjures negative images and stereotypes, but most people have been infected with some form of the virus. For most, a sore appears, heals and is forgotten, although the virus remains latent just waiting for the right circumstances to come back. Now, the mystery behind what triggers the virus to become active again is closer to being solved thanks to new research published in the Journal of Leukocyte Biology's November 2012 issue.

1 Nov 2012

Eliminating bacteria's DNA, boosting antimicrobial proteins may help prevent recurrent ear infections

Eliminating bacteria's DNA and boosting antimicrobial proteins that already exist may help prevent middle ear infections from reoccurring. These are the findings from a Nationwide Children's Hospital study that examined how an immune defense protein common in the middle ear interacts with a structure meant to protect a colony of bacteria.

31 Oct 2012

Sea water strengthens the body against viruses, low defences, bacteria and pathogens

Sea water therapy is a technique of cellular nutrition backed by more than 100 years of clinical use in hospitals, during which numerous studies have demonstrated its beneficial effects on patients' health.

29 Oct 2012

Cellectis announces successful programming of immune system cells to kill cancer cells

Cellectis, the genome engineering specialist, has announced successfully programming cells from the immune system (T cells) to kill cancer cells. This technological breakthrough was revealed for the first time ever on Saturday, October 27th at the congress of the ESGCT (European Society of Gene & Cell Therapy) in Versailles, outside Paris.

29 Oct 2012

FDA report says pharmacy knew about contamination problems

A federal inspection of a company whose tainted pain medicine has caused one of the worst public health drug disasters since the 1930s found greenish-yellow residue on sterilization equipment, surfaces coated with levels of mold and bacteria that exceeded the company's own environmental limits, and an air-conditioner that was shut off nightly despite the importance of controlling temperature and humidity.

29 Oct 2012

Scientists hope to unravel mystery of how Borrelia burgdorferi causes Lyme disease

Investigators at The University of Texas Health Science Center at Houston (UTHealth) have accelerated the search for the bacterial genes that make the Lyme disease bacterium so invasive and persistent. The discovery could advance the diagnosis and treatment of this disease, which affects an estimated 30,000 Americans each year.

29 Oct 2012

Universal approach to MRSA-prevention in ICU is most effective

Universal decolonization of all patients admitted to intensive care units using chlorhexidine baths and mupirocin treatment for 5 days significantly reduces the risk for infection with methicillin-resistant Staphylococcus aureus , report researchers.

26 Oct 2012

Researchers figure out 3D shape of promising TB drug target

Researchers at Johns Hopkins have figured out the three-dimensional shape of the protein responsible for creating unique bonds within the cell wall of the bacteria that cause tuberculosis. The bonds make the bacteria resistant to currently available drug therapies, contributing to the alarming rise of these super-bacteria throughout the world.

26 Oct 2012

CUMC researchers develop first true mouse model of typhoid infection

Columbia University Medical Center (CUMC) researchers have created the first true mouse model of typhoid infection. The development promises to advance the study of typhoid and the creation of new vaccines against the infection, which remains a major health threat in developing countries.

26 Oct 2012

Artificial CSP proteins reduce S. pneumoniae competence y more than 90%

The bacterium Streptococcus pneumoniae - which can cause pneumonia, meningitis, bacteremia and sepsis - likes to share its antibiotic-defeating weaponry with its neighbors. Individual cells can pass resistance genes to one another through a process called horizontal gene transfer, or by "transformation," the uptake of DNA from the environment.

26 Oct 2012

Durata completes target enrollment in dalbavancin Phase 3 trial for ABSSSI

Durata Therapeutics today announced that it has completed its target enrollment for DISCOVER 2 ("Dalbavancin for Infections of the Skin COmpared to Vancomycin at an Early Response"), the second global, Phase 3 clinical trial of Durata's lead product candidate, dalbavancin, under investigation for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacteria.

26 Oct 2012

Bacteria News and Research

WSU researcher receives NSF fund to study on antibiotic resistance

Mass spectrometry can help visualize how drugs work inside living cells to kill infectious microbes

Researcher identifies 71 genetic regions newly associated with inflammatory bowel disease

MH6 vaccine shows promise in treating meth addiction

Nisin may slow or prevent squamous cell head and neck cancers

Microbiologists confirm existence of new tick disease in Switzerland

Scientists solve mystery behind what triggers the herpes virus to become active again

Eliminating bacteria's DNA, boosting antimicrobial proteins may help prevent recurrent ear infections

Sea water strengthens the body against viruses, low defences, bacteria and pathogens

Cellectis announces successful programming of immune system cells to kill cancer cells

FDA report says pharmacy knew about contamination problems

Scientists hope to unravel mystery of how Borrelia burgdorferi causes Lyme disease

Universal approach to MRSA-prevention in ICU is most effective

Researchers figure out 3D shape of promising TB drug target

CUMC researchers develop first true mouse model of typhoid infection

Artificial CSP proteins reduce S. pneumoniae competence y more than 90%

Durata completes target enrollment in dalbavancin Phase 3 trial for ABSSSI

New study finds bacteria cue single-celled choanoflagellates to form colonies

Simple tricks to keep mold and dust mites at bay during winter

New method of oral vaccination could help boost immunity to TB, influenza and C. difficile

Microbiology eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News